Lee Y.-L.KUAN-YIN LINCheng S.-H.Lu P.-L.Wang N.-C.Ho M.-W.Yang C.-J.Liou B.-H.Tang H.-J.Huang S.-S.Huang S.-H.Chen T.-C.Lin C.-Y.Lin S.-P.Lee Y.-T.CHIEN-CHING HUNGTaiwan HIV Study Group2021-08-272021-08-2720210924-8579https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111970673&doi=10.1016%2fj.ijantimicag.2021.106403&partnerID=40&md5=403d5ec5432ddbf9cce8e88921ebae30https://scholars.lib.ntu.edu.tw/handle/123456789/579794Real-world experience with dolutegravir (DTG) plus boosted protease inhibitor (bPI) as a two-drug regimen is limited for highly experienced HIV-positive patients with virological failure or intolerance to antiretroviral therapy. Patients receiving DTG plu[SDGs]SDG3dolutegravir; proteinase inhibitor; antiretrovirus agent; dipyrone; fused heterocyclic rings; integrase inhibitor; oxazine derivative; piperazine derivative; adult; antiretroviral therapy; antiviral resistance; Article; body weight gain; combination drugjournal article10.1016/j.ijantimicag.2021.106403342894042-s2.0-85111970673